Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
46.58
-0.31 (-0.66%)
At close: Nov 20, 2024, 4:00 PM
45.00
-1.58 (-3.39%)
Pre-market: Nov 21, 2024, 5:25 AM EST
Tarsus Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Revenue | 129.62 | 17.45 | 25.82 | 57.03 | - | - | Upgrade
|
| Revenue Growth (YoY) | 801.96% | -32.42% | -54.73% | - | - | - | Upgrade
|
| Cost of Revenue | 58.93 | 51.91 | 43.58 | 43.79 | 18.83 | - | Upgrade
|
| Gross Profit | 70.69 | -34.46 | -17.76 | 13.24 | -18.83 | - | Upgrade
|
| Selling, General & Admin | 211.29 | 108.7 | 44.95 | 25.4 | 8.17 | 1.14 | Upgrade
|
| Research & Development | - | - | - | - | - | 3.16 | Upgrade
|
| Operating Expenses | 211.29 | 108.7 | 44.95 | 25.4 | 8.17 | 4.3 | Upgrade
|
| Operating Income | -140.6 | -143.16 | -62.71 | -12.16 | -27 | -4.3 | Upgrade
|
| Interest Expense | -6.53 | -3.35 | -2.2 | - | - | -0.1 | Upgrade
|
| Interest & Investment Income | 14.35 | 10.34 | 3.5 | 0.04 | 0.19 | 0.06 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.91 | -0.1 | 0.09 | -0 | - | -0.08 | Upgrade
|
| EBT Excluding Unusual Items | -131.87 | -136.27 | -61.33 | -12.12 | -26.81 | -4.41 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.53 | 0.38 | -0.77 | -1.58 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | -0.07 | - | - | Upgrade
|
| Other Unusual Items | -1.94 | - | - | - | - | -0.26 | Upgrade
|
| Pretax Income | -134.34 | -135.89 | -62.1 | -13.77 | -26.81 | -4.67 | Upgrade
|
| Income Tax Expense | - | - | -0 | 0.06 | 0 | 0 | Upgrade
|
| Net Income | -134.34 | -135.89 | -62.09 | -13.83 | -26.81 | -4.67 | Upgrade
|
| Net Income to Common | -134.34 | -135.89 | -62.09 | -13.83 | -26.81 | -4.67 | Upgrade
|
| Shares Outstanding (Basic) | 36 | 29 | 25 | 21 | 6 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 36 | 29 | 25 | 21 | 6 | 2 | Upgrade
|
| Shares Change (YoY) | 30.92% | 19.35% | 19.78% | 231.12% | 162.72% | 34.29% | Upgrade
|
| EPS (Basic) | -3.70 | -4.62 | -2.52 | -0.67 | -4.32 | -1.98 | Upgrade
|
| EPS (Diluted) | -3.70 | -4.62 | -2.52 | -0.67 | -4.32 | -1.98 | Upgrade
|
| Free Cash Flow | -101.68 | -119 | -49.54 | 3.16 | -21.59 | -3.85 | Upgrade
|
| Free Cash Flow Per Share | -2.80 | -4.05 | -2.01 | 0.15 | -3.48 | -1.63 | Upgrade
|
| Gross Margin | 54.53% | -197.50% | -68.81% | 23.22% | - | - | Upgrade
|
| Operating Margin | -108.47% | -820.53% | -242.92% | -21.32% | - | - | Upgrade
|
| Profit Margin | -103.64% | -778.89% | -240.51% | -24.25% | - | - | Upgrade
|
| Free Cash Flow Margin | -78.44% | -682.04% | -191.88% | 5.54% | - | - | Upgrade
|
| EBITDA | -139.46 | -142.28 | -62.39 | -11.85 | -26.9 | -4.26 | Upgrade
|
| EBITDA Margin | -107.59% | - | -241.66% | -20.77% | - | - | Upgrade
|
| D&A For EBITDA | 1.14 | 0.88 | 0.33 | 0.31 | 0.1 | 0.04 | Upgrade
|
| EBIT | -140.6 | -143.16 | -62.71 | -12.16 | -27 | -4.3 | Upgrade
|
| EBIT Margin | -108.47% | - | -242.92% | -21.32% | - | - | Upgrade
|
| Revenue as Reported | 129.62 | 17.45 | 25.82 | 57.03 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.